tiprankstipranks
Trending News
More News >

ANGLE plc Reports Revenue Growth and Strategic Pharma Partnerships in 2024

Story Highlights
ANGLE plc Reports Revenue Growth and Strategic Pharma Partnerships in 2024

Confident Investing Starts Here:

The latest update is out from ANGLE plc ( (GB:AGL) ).

ANGLE plc reported a 31% increase in revenue for 2024, driven by its strategic focus on large pharmaceutical contracts, despite challenges in product sales due to regulatory changes and reduced research funding. The company has streamlined operations and secured multiple agreements with major pharma companies, positioning itself for sustainable growth and future collaborations. ANGLE’s advancements in next-generation sequencing assays and its pivotal role in groundbreaking cancer research highlight its potential impact on the industry. While the company anticipates modest revenue growth in 2025, it remains optimistic about converting ongoing discussions into substantial opportunities.

The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

More about ANGLE plc

ANGLE plc is a leading company in the liquid biopsy industry, specializing in circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company focuses on innovative technologies for cancer diagnostics and has established significant partnerships with large pharmaceutical companies to enhance drug discovery and development.

Average Trading Volume: 1,093,524

Technical Sentiment Signal: Sell

Current Market Cap: £33.86M

See more insights into AGL stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App